肿瘤抗血管生成治疗耐药机制
收稿日期: 2024-04-24
修回日期: 2024-08-20
网络出版日期: 2024-08-27
基金资助
国家自然科学基金面上项目(82172353);黑龙江省省属科研院所科研业务费项目(CZKYF2021-2-B012);中国博士后科学基金特别资助(2020T130159);黑龙江省博士后特别资助(LBH-TZ2020);黑龙江省自然科学基金项目(YQ2022H004);黑龙江省头雁创新团队项目资助
Drug resistance mechanism of anti-angiogenesis therapy in tumor
Received date: 2024-04-24
Revised date: 2024-08-20
Online published: 2024-08-27
Supported by
National Natural Science Foundation of China(82172353);Research Business Funding Projects for Provincial Scientific Research Institutions in Heilongjiang Province(CZKYF2021-2-B012);China Postdoctoral Science Foundation(2020T130159);Heilongjiang Postdoctoral Financial Assistance(LBH-TZ2020);Natural Science Foundation of Heilongjiang Province of China(YQ2022H004);Heilongjiang Province Head Goose Innovation Team Project
血管生成指的是通过内皮细胞的迁移、增殖和分化，从现有血管网络中形成新的血管网络的过程。这一过程对于实体肿瘤的生长和扩散至关重要，尤其是在肿瘤体积超过2 mm3之后，新生的血管网络为肿瘤提供了至关重要的氧气、营养及生长因子。抗血管生成已经成为临床常用靶向治疗肿瘤的方案之一。首个抗血管生成药物贝伐单抗已广泛应用于多种实体肿瘤治疗，但由于获得性耐药现象，疗效仅能维持1~2年。即使血管内皮细胞的基因组相对稳定，不易产生耐药性，但临床实践中仍观察到多种类型的耐药现象，这表明抗血管生成治疗的耐药问题仍然是一个具有挑战性的研究领域。本文主要综述了肿瘤抗血管生成治疗耐药机制的最新进展，并探讨了抗肿瘤血管生成治疗的新前景，以期为临床实践提供有力的理论支持和指导。
闫旭, 郭影, 孙冬琳, 吴楠, 金焰 . 肿瘤抗血管生成治疗耐药机制[J]. 遗传, 2024 , 46(11) : 911 -919 . DOI: 10.16288/j.yczz.24-110
Angiogenesis refers to the process of forming a new network of blood vessels from existing ones through the migration, proliferation, and differentiation of endothelial cells. This process is crucial for the growth and spread of solid tumors, particularly once the tumor volume exceeds 2 mm3, as the newly formed vascular network provides essential oxygen, nutrients, and growth factors to the tumor. Anti-angiogenesis therapy has become one of the commonly used targeted treatments for cancer in clinical practice. Bevacizumab, the first anti-angiogenesis drug, has been widely applied in the treatment of various solid tumors. However, due to acquired resistance, its efficacy is typically sustained for only 1 to 2 years. Despite the relative genomic stability of endothelial cells, which makes resistance less likely, various types of resistance phenomena have been observed in clinical practice, indicating that resistance to anti-angiogenic therapy remains a challenging research area. This review focuses on the latest advances in the mechanisms of resistance to anti-angiogenic therapy in tumors and explores new prospects for anti-tumor angiogenesis treatment, in order to provide strong theoretical support and guidance for clinical practice.
| [1] | Naito H, Iba T, Takakura N. Mechanisms of new blood-vessel formation and proliferative heterogeneity of endothelial cells. Int Immunol, 2020, 32(5): 295-305. |
| [2] | Lopes-Coelho F, Martins F, Pereirs SA, Serpa J. Anti-angiogenic therapy: current challenges and future perspectives. Int J Mol Sci, 2021, 22(7): 3765. |
| [3] | Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971, 285(21): 1182-1186. |
| [4] | Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin?) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev, 2020, 86: 102017. |
| [5] | Teuwen LA, De Rooij LPMH, Cuypers A, Rohlenova K, Dumas SJ, García-Caballero M, Meta E, Amersfoort J, Taverna F, Becker LM, Veiga N, Cantelmo AR, Geldhof V, Conchinha NV, Kalucka J, Treps L, Conradi LC, Khan S, Karakach TK, Soenen S, Vinckier S, Schoonjans L, Eelen G, Van Laere S, Dewerchin M, Dirix L, Mazzone M, Luo YL, Vermeulen P, Carmeliet P. Tumor vessel co-option probed by single-cell analysis. Cell Rep, 2021, 35(11): 109253. |
| [6] | Lazaris A, Amri A, Petrillo SK, Zoroquiain P, Ibrahim N, Salman A, Gao ZH, Vermaulen PB, Metrakos P. Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies. J Pathol Clin Res, 2018, 4(3): 184-192. |
| [7] | Pezzella F, Ribatti D. Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies. Cancer Rep (Hoboken), 2022, 5(12): e1318. |
| [8] | Ribatti D, Annese T, Tamma R. Vascular co-option in resistance to anti-angiogenic therapy. Front Oncol, 2023, 13: 1323350. |
| [9] | Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, Trent JM, Meltzer PS, Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol, 1999, 155(3): 739-752. |
| [10] | He M, Yang H, Shi HC, Hu YX, Chang CS, Liu SF, Yeh SY. Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR/ERβ/Hif2-α signaling. Cancer Lett, 2022, 524: 15-28. |
| [11] | Wei Z, Lei M, Wang YH, Xie YZ, Xie XY, Lan DW, Jia YB, Liu JY, Ma YF, Cheng B, Gerecht S, Xu F. Hydrogels with tunable mechanical plasticity regulate endothelial cell outgrowth in vasculogenesis and angiogenesis. Nat Commun, 2023, 14(1): 8307. |
| [12] | Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci, 2020, 77(9): 1745-1770. |
| [13] | Saravanan S, Vimalraj S, Pavani K, Nikarika R, Sumantran VN. Intussusceptive angiogenesis as a key therapeutic target for cancer therapy. Life Sci, 2020, 252: 117670. |
| [14] | Ayala-Domínguez L, Olmedo-Nieva L, Mu?oz-Bello JO, Contreras-Paredes A, Manzo-Merino J, Martínez-Ramírez I, Lizano M. Mechanisms of vasculogenic mimicry in ovarian cancer. Front Oncol, 2019, 9: 998. |
| [15] | Akwii RG, Mikelis CM. Targeting the angiopoietin/tie pathway: prospects for treatment of retinal and respiratory disorders. Drugs, 2021, 81(15): 1731-1749. |
| [16] | Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol, 2018, 15(5): 325-340. |
| [17] | Hosaka K, Yang YL, Seki T, Du QQ, Jing X, He XK, Wu JY, Zhang Y, Morikawa H, Nakamura M, Scherzer M, Sun XT, Xu YF, Cheng T, Li XR, Liu XL, Li Q, Liu YZ, Hong A, Chen YG, Cao YH. Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors. Nat Commun, 2020, 11(1): 3704. |
| [18] | Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther, 2023, 8(1): 198. |
| [19] | Kalra VK, Zhang SX, Malik P, Tahara SM. Placenta growth factor mediated gene regulation in sickle cell disease. Blood Rev, 2018, 32(1): 61-70. |
| [20] | Arai H, Battaglin F, Wang JY, Lo JH, Soni S, Zhang W, Lenz HJ. Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev, 2019, 81: 101912. |
| [21] | Itatani Y, Kawada K, Yamamoto T, Sakai Y. Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway. Int J Mol Sci, 2018, 19(4): 1232. |
| [22] | Cheng Y, Li SJ, Hou YY, Wan WJ, Wang K, Fu SH, Yuan Y, Yang KD, Ye XF. Glioma-derived small extracellular vesicles induce pericyte-phenotype transition of glioma stem cells under hypoxic conditions. Cell Signal, 2023, 109: 110754. |
| [23] | Pineda E, Salud A, Vila-Navarro E, Safont MJ, Llorente B, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Pérez-Carrión R, Carmona A, Ayuso JR, Ripollés T, Bouzas R, Gironella M, García-Albéniz X, Feliu J, Maurel J. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: a prospective translational study in the BECOX (GEMCAD 09-01) trial. Tumour Biol, 2017, 39(6): 1010428317705509. |
| [24] | Jung K, Heishi T, Incio J, Huang YH, Beech EY, Pinter M, Ho WW, Kawaguchi K, Rahbari NN, Chung E, Kim JK, Clark JW, Willett CG, Yun SH, Luster AD, Padera TP, Jain RK, Fukumura D. Targeting CXCR4-dependent immunosuppressive Ly6C(low) monocytes improves antiangiogenic therapy in colorectal cancer. Proc Natl Acad Sci USA, 2017, 114(39): 10455-10460. |
| [25] | Martin JD, Seano G, Jain RK. Normalizing function of tumor vessels: progress, opportunities, and challenges. Annu Rev Physiol, 2019, 81: 505-534. |
| [26] | Chen WZ, Jiang JX, Yu XY, Xia WJ, Yu PX, Wang K, Zhao ZY, Chen ZG. Endothelial cells in colorectal cancer. World J Gastrointest Oncol, 2019, 11(11): 946-956. |
| [27] | Eikesdal HP, Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol, 2009, 19(5): 310-317. |
| [28] | Patel SA, Nilsson MB, Le XN, Cascone T, Jain RK, Heymach JV. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin Cancer Res, 2023, 29(1): 30-39. |
| [29] | Goveia J, Rohlenova K, Taverna F, Treps L, Conradi LC, Pircher A, Geldhof V, De Rooij LPMH, Kalucka J, Sokol L, García-Caballero M, Zheng YF, Qian JB, Teuwen LA, Khan S, Boeckx B, Wauters E, Decaluwé H, De Leyn P, Vansteenkiste J, Weynand B, Sagaert X, Verbeken E, Wolthuis A, Topal B, Everaerts W, Bohnenberger H, Emmert A, Panovska D, De Smet F, Staal FJT, Mclaughlin RJ, Impens F, Lagani V, Vinckier S, Mazzone M, Schoonjans L, Dewerchin M, Eelen G, Karakach TK, Yang HM, Wang J, Bolund L, Lin L, Thienpont B, Li XR, Lambrechts D, Luo YL, Carmeliet P. An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates. Cancer Cell, 2020, 37(1): 21-36.e13. |
| [30] | Zhao Q, Eichten A, Parveen A, Adler C, Huang Y, Wang W, Ding YM, Adler A, Nevins T, Ni M, Wei Y, Thurston G. Single-cell transcriptome analyses reveal endothelial cell heterogeneity in tumors and changes following antiangiogenic treatment. Cancer Res, 2018, 78(9): 2370-2382. |
| [31] | Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther, 2021, 221: 107753. |
| [32] | Song S, Zhang GH, Chen XT, Zheng J, Liu XD, Wang YQ, Chen ZJ, Wang YX, Song YL, Zhou Q. HIF-1α increases the osteogenic capacity of ADSCs by coupling angiogenesis and osteogenesis via the HIF-1α/VEGF/AKT/ mTOR signaling pathway. J Nanobiotechnology, 2023, 21(1): 257. |
| [33] | Qi SY, Deng SL, Lian ZX, Yu K. Novel drugs with high efficacy against tumor angiogenesis. Int J Mol Sci, 2022, 23(13): 6934. |
| [34] | Loizzi V, Del Vecchio V, Gargano G, De Liso M, Kardashi A, Naglieri E, Resta L, Cicinelli E, Cormio G. Biological pathways involved in tumor angiogenesis and Bevacizumab based anti-angiogenic therapy with special references to ovarian cancer. Int J Mol Sci, 2017, 18(9): 1967. |
| [35] | Huang CB, Li ZX, Li N, Li Y, Chang AT, Zhao TS, Wang XC, Wang HW, Gao S, Yang SY, Hao JH, Ren H. Interleukin 35 expression correlates with microvessel density in pancreatic ductal adenocarcinoma, recruits monocytes, and promotes growth and angiogenesis of xenograft tumors in mice. Gastroenterology, 2018, 154(3): 675-688. |
| [36] | Castro B A, Flanigan P, Jahangiri A, Hoffman D, Chen W, Kuang R, De Lay M, Yagnik G, Wagner JR, Mascharak S, Sidorov M, Shrivastav S, Kohanbash G, Okada H, Aghi MK. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene, 2017, 36(26): 3749-3759. |
| [37] | Goto H, Nishioka Y. Fibrocytes: a novel stromal cells to regulate resistance to anti-angiogenic therapy and cancer progression. Int J Mol Sci, 2017, 19(1): 98. |
| [38] | Cheng J, Wei JW, Tong T, Sheng WQ, Zhang YL, Han YQ, Gu DS, Hong N, Ye YJ, Tian J, Wang Y. Prediction of histopathologic growth patterns of colorectal liver metastases with a noninvasive imaging method. Ann Surg Oncol, 2019, 26(13): 4587-4598. |
| [39] | Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Aghajanian C, Samuelson MI, Lankes HA, Soslow RA, Leslie KK. TP53 sequencing and p53 immunohistochemistry predict outcomes when Bevacizumab is added to frontline chemotherapy in endometrial cancer: an NRG oncology/gynecologic oncology group study. J Clin Oncol, 2022, 40(28): 3289-3300. |
| [40] | Brenner A, Zuniga R, Sun JD, Floyd J, Hart CP, Kroll S, Fichtel L, Cavazos D, Caflisch L, Gruslova A, Huang S, Liu YC, Lodi A, Tiziani S. Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study. Neuro Oncol, 2018, 20(9): 1231-1239. |
| [41] | Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I. Atezolizumab and platinum plus pemetrexed with or without Bevacizumab for metastatic nonsquamous non-small cell lung cancer: a phase 3 Randomized clinical trial. JAMA Oncol, 2024, 10(3): 315-324. |
| [42] | Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F, Yu S, The HH, Martarello L, Gassner C, Stubenrauch KG, Munro K, Augustin HG, Thomas M. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res, 2013, 19(24): 6730-6740. |
| [43] | Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol, 2014, 15(8): 799-808. |
| [44] | Belotti D, Pinessi D, Taraboletti G. Alternative vascularization mechanisms in tumor resistance to therapy. Cancers (Basel), 2021, 13(8): 1912. |
| [45] | Klemke L, De Oliveira T, Witt D, Winkler N, Bohnenberger H, Bucala R, Conradi LC, Schulz-Heddergott R. Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer. Cell Death Dis, 2021, 12(2): 155. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:
